Disclosure: PeptideOnline earns commissions from some links on this page, at no extra cost to you. See our affiliate disclosure.
The short answer
Health insurance may cover FDA-approved peptide drugs when they are prescribed for an approved use that your plan includes on its formulary, often with prior authorization. Compounded peptides are usually not covered and are paid out of pocket. Research-use-only peptides are never covered, because they are not drugs approved or dispensed for human use.
Medicare has its own rules: Part D plans are barred by statute from covering drugs used for weight loss, but they can cover the same molecules for other approved uses, and a separate GLP-1 pilot launched in July 2026. Details follow.
- Coverage is tied to an FDA-approved product, an approved indication, and your plan's formulary rules.
- The same molecule can be covered for one diagnosis and excluded for another.
- Compounded versions are not FDA-approved and rarely appear on formularies.
- Research-use-only peptides are never insurance-eligible.
Category 1: FDA-approved peptide drugs
Several peptide or peptide-based drugs are FDA-approved, which makes them eligible for coverage in principle. Whether your plan covers one depends on the diagnosis and the plan's rules. Examples:
- Tirzepatide. Sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. See our tirzepatide profile and the sleep apnea approval.
- Semaglutide. Ozempic and Rybelsus for type 2 diabetes; Wegovy for weight management and for additional indications. Profile: semaglutide.
- Tesamorelin. Egrifta is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Insurers commonly publish prior-authorization criteria for it. Profile: tesamorelin.
- Bremelanotide. Vyleesi is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Background: PT-141 (bremelanotide) guide.
It's also worth remembering how broad the word "peptide" is. Insulin is a peptide hormone, and many long-established prescription drugs are peptides or peptide analogues. Those are routinely covered for their approved uses, which is a useful reminder that insurers don't decide coverage based on whether something is a peptide. They decide based on approval status, indication and plan rules, the same as for any other drug.
What decides coverage for approved drugs
- Indication. Plans typically cover a drug for its labeled use and may exclude other uses. A drug covered for diabetes may be excluded when prescribed for weight loss.
- Formulary tier. Determines your copay or coinsurance.
- Prior authorization. Your prescriber submits documentation that you meet the plan's criteria.
- Step therapy. Some plans require trying another drug first.
- Plan exclusions. Some employer plans exclude entire categories, such as anti-obesity drugs.
Medicare in 2026
According to AARP's coverage explainer (updated August 26, 2026), the 2003 law that created Part D prohibits Part D plans from covering anti-obesity medications, along with drugs for weight gain, cosmetic purposes, fertility, hair growth and sexual dysfunction. That exclusion is why Vyleesi falls outside Part D, and why GLP-1 coverage depends on the diagnosis:
- Ozempic, Rybelsus and Mounjaro can be covered for type 2 diabetes.
- Wegovy can be covered for cardiovascular disease and for MASH, a serious liver disease.
- Plans may require proof of diagnosis and trying other drugs first.
The GLP-1 Bridge pilot. AARP reports an 18-month Medicare pilot that operates outside Part D, launched in July 2026 and running through December 2027. Eligible beneficiaries can get Wegovy injections or tablets, Foundayo tablets, or the Zepbound KwikPen for a $50 monthly copay, as of AARP's August 2026 update. Eligibility includes being at least 18 with a BMI of 35 or higher, or lower BMI thresholds combined with certain conditions; prior authorization is required for the first prescription. Beneficiaries already receiving GLP-1 coverage through Part D for another reason are not eligible. Confirm current terms with Medicare or your plan, since pilot details can change.
Category 2: Compounded peptides
Compounded drugs are not FDA-approved. They are prepared by a pharmacy for an individual prescription. Most commercial plans do not list compounded GLP-1s or other compounded peptides on their formularies, so patients usually pay cash. Some people use HSA or FSA funds for compounded prescriptions instead; our guide to using an HSA or FSA for peptide therapy explains when that works.
Compounded products also sit in a shifting regulatory space. Regulatory status for individual peptides has been changing through 2026, so a product available from a compounder today may not be next year.
Category 3: Research-use-only peptides
Products sold "for research use only" are not drugs approved or dispensed for human use. No insurer covers them, they are not HSA or FSA eligible, and there is no prescriber or pharmacy in the chain. Peptides such as BPC-157, TB-500 or epitalon that are sold this way are outside the insurance system entirely.
Coverage at a glance
| Category | Examples | Commercial insurance | Medicare Part D |
|---|---|---|---|
| FDA-approved, on-label | Mounjaro for diabetes; Egrifta for HIV lipodystrophy | Often covered with prior authorization | Often covered, plan rules apply |
| FDA-approved, weight-loss indication | Zepbound, Wegovy for weight management | Varies widely; some plans exclude | Excluded by statute (separate pilot may apply) |
| FDA-approved, excluded category | Vyleesi (sexual dysfunction) | Varies by plan | Excluded by statute |
| Compounded | Compounded semaglutide or tirzepatide | Rarely covered | Generally not covered |
| Research use only | BPC-157, TB-500 sold as reagents | Never | Never |
How to check your own coverage
- Get the exact drug name and indication from your prescriber.
- Search your plan's formulary for the brand name. Note the tier and any "PA" (prior authorization), "ST" (step therapy) or "QL" (quantity limit) codes.
- Call the number on your card and ask whether the drug is covered for your diagnosis, not just in general.
- Ask your prescriber to submit prior authorization with the documentation the plan lists.
- If denied, ask for the denial in writing, including the specific criterion you didn't meet, and ask about the appeal process and deadline.
If coverage isn't available, compare total costs across options using our peptide therapy cost breakdown.
If the answer is no: exceptions and appeals
A denial is not always final. Common routes:
- Formulary exception. If the drug isn't on your plan's formulary, your prescriber can request an exception, explaining why covered alternatives aren't appropriate for you.
- Internal appeal. You can ask the plan to reconsider a prior-authorization denial. Include the specific criteria from the denial letter and the clinical documentation that addresses each one.
- External review. For many plans, if the internal appeal fails, you can request review by an independent organization. Your denial letter should explain the process and deadlines.
- Employer plan design. If your plan excludes a whole category, such as anti-obesity drugs, an appeal on medical grounds usually won't change that. The exclusion is a benefit decision by the plan sponsor, often your employer's HR or benefits team.
Cash-pay routes for approved drugs
When insurance won't pay, some people still use the FDA-approved product rather than a compounded version. Manufacturers of several GLP-1 drugs run savings programs and direct-to-patient pharmacy options, and terms change frequently. Copay savings cards generally can't be used with Medicare or other federal coverage. Check the manufacturer's own site for current terms rather than relying on third-party summaries, and compare the total cost with any compounded option, keeping in mind that compounded drugs are not FDA-approved.
Whatever route you choose, keep itemized receipts. If you have an HSA or FSA, prescribed drugs can often be paid from it; we covered the rules in a separate guide.
Frequently asked questions
Does insurance cover peptide therapy?
Insurance may cover FDA-approved peptide drugs prescribed for approved uses on your plan's formulary, often with prior authorization. Compounded peptides are rarely covered, and research-use-only peptides are never covered.
Does Medicare cover Zepbound or Wegovy for weight loss?
Part D plans are barred by law from covering anti-obesity drugs. They can cover the same molecules for other approved uses, such as Wegovy for cardiovascular disease. A separate Medicare GLP-1 pilot launched in July 2026 with its own eligibility rules.
Is compounded semaglutide covered by insurance?
Usually not. Compounded drugs are not FDA-approved and rarely appear on formularies, so most patients pay out of pocket.
Does insurance cover tesamorelin?
Egrifta, the FDA-approved tesamorelin product, is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Insurers commonly cover it for that indication with prior authorization criteria.
Why was my GLP-1 covered for diabetes but not for weight loss?
Coverage is tied to the diagnosis and the plan's rules. Many plans, and Medicare Part D by statute, exclude drugs used for weight loss even when the same molecule is covered for diabetes.
Sources and primary references
- AARP: Does Medicare Cover Ozempic and Other Weight-Loss Drugs? (updated August 26, 2026)
- FDA label: Egrifta (tesamorelin), indication
- Example insurer prior-authorization policy: Tesamorelin (Egrifta SV, Egrifta WR)
- Oregon Drug Use Review: bremelanotide (Vyleesi) drug review
Regulatory status can change. PeptideOnline date-stamps regulatory summaries and links to primary agency sources so readers can verify the current position.
Medical disclaimer: This article is for educational and research-information purposes only. It does not provide diagnosis, prescribing, dosing, injection, or individualized treatment advice. It has not been reviewed by a clinician. FDA-approved drugs, compounded prescription products, and research-use chemicals are different product categories and should not be treated as interchangeable. See our medical disclaimer and editorial policy.